SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Ann Richards Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAnn Richards
Date of birth1933-09-01
IdentifiersMRN HR-ML019-SYN-TD; SSN (made up) 000-19-3381
Document date2026-11-01
AuthorRosalind Teague, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for bone health after a fall with a hand fracture. Concerns: She does not want to break bones and lose her posture the way her mother did; She wants to keep traveling and speaking without slowing down, and wants a plan she can keep on the road. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 50 mcg (1971 units) oral tablet, one tablet dailyOne tablet by mouth dailyOral route1997-02-10activeS
Zoledronic acid 5 mg in 100 mL intravenous infusion over 30 minutes, once every 12 monthsOnce every 12 months, given in the clinic infusion room after a calcium and creatinine checkIntravenous route1997-05-12activeS
Acetaminophen 500 mg oral tablet, two tablets every 6 hours as needed for aches or fever for up to three days after the infusion (no more than 3 g a day)Two tablets every 6 hours as needed for up to three days after the infusionOral route1997-05-12 to 1997-05-15completedS

Procedures

ProcedureDatesStatusEvidence
Dual-energy X-ray absorptiometry of the lumbar spine and hip: L1-L4 T-score -2.3, femoral neck -2.0, total hip -1.7 (low bone mass)1997-02-10 to 1997-02-10completedS
Vertebral fracture assessment by lateral spine DXA, T4 to L4: no vertebral fracture; mild degenerative change1997-02-10 to 1997-02-10completedS
Supervised balance and strength exercise program with a physical therapist, 16 sessions over eight weeks, then a home program1997-03-16 to 1997-05-08completedS
Zoledronic acid 5 mg intravenous infusion over 30 minutes, first yearly dose, after a normal calcium, creatinine, and vitamin D check1997-05-12 to 1997-05-12completedS
Advance care planning conversation, about 20 minutes1997-10-06 to 1997-10-06completedS

Immunizations

DateVaccineStatusEvidence
1996-10-14Influenza vaccine, 1996-1997 seasoncompletedS
1994-05-16Recombinant zoster vaccine, two-dose series completedcompletedS
1990-06-11Tdap vaccinecompletedS
1997-10-06Influenza vaccine, 1997-1998 seasoncompletedS
1997-10-06Pneumococcal conjugate vaccine PCV20, single dosecompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1980Heavy drinking, followed by treatment from which she emerged sober; no alcohol sinceD (CLM-0003)
1996Fall with a hand fracture (one account also describes a second fall with an ankle fracture); the year is 1996 in two sources and 1994 in oneD (CLM-0006)
1996Bone density test after the fall, reported as osteopenia, an early stage of osteoporosis; no report or T-scores availableD (CLM-0005, CLM-0007)

Family History

RelativeConditionAge at deathEvidence
motherOsteoporosis with fractures of the arm and hip and a curved upper back, by Richards's own public account; Richards said osteoporosis was not the cause of her mother's death but led to itD (CLM-0004)

Health Concerns

ConcernStatusEvidence
She does not want to break bones and lose her posture the way her mother didactiveS
She wants to keep traveling and speaking without slowing down, and wants a plan she can keep on the roadactiveS

Assessment

Most recent measures: DXA Lumbar spine [T-score] Bone density -2.3 on 1997-02-10; DXA Femur [T-score] Bone density -2 on 1997-02-10; DXA Hip [T-score] Bone density -1.7 on 1997-02-10; Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment 22 on 1997-02-10; Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment 3.6 on 1997-02-10; Calcium [Mass/volume] in Serum or Plasma 9.3 on 1997-08-11; Albumin [Mass/volume] in Serum or Plasma 4.2 on 1997-02-10; Creatinine [Mass/volume] in Serum or Plasma 0.8 on 1997-05-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1992)/1.73 sq M 81 on 1997-05-12; Phosphate [Mass/volume] in Serum or Plasma 3.5 on 1997-02-10; Magnesium [Mass/volume] in Serum or Plasma 2 on 1997-02-10; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 on 1997-02-10; Parathyrin.intact [Mass/volume] in Serum or Plasma 54 on 1997-02-10; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 1997-02-10; Hemoglobin [Mass/volume] in Blood 13.3 on 1997-02-10; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 21 on 1997-02-10; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 on 1997-05-12; Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma 190 on 1997-08-11; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 1997-02-10; Total score [AUDIT-C] 0 on 1997-10-06; Calcium [Mass/time] in 24 hour Urine 172 on 1997-05-12; Cholesterol [Mass/volume] in Serum or Plasma 204 on 1997-10-06; Cholesterol in HDL [Mass/volume] in Serum or Plasma 62 on 1997-10-06; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 118 on 1997-10-06; Triglyceride [Mass/volume] in Serum or Plasma 120 on 1997-10-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1997-10-06 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 1991 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold)activeconfirmed M85.89S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture.
Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol sinceactiveconfirmed F10.21S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit.
History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls sinceactiveconfirmed Z91.81S — Synthetic modern entry linked to her publicly described falls and fractures.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1997-02-10DXA Lumbar spine [T-score] Bone density-2.3{T-score}-1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosisLowS
1997-02-10DXA Femur [T-score] Bone density-2{T-score}-1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosisLowS
1997-02-10DXA Hip [T-score] Bone density-1.7{T-score}-1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosisLowS
1997-02-10Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment22%S
1997-02-10Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment3.6%S
1997-02-10Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1997-02-10Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
1997-02-10Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1 mg/dLNormalS
1997-02-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1992)/1.73 sq M81mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1997-02-10Phosphate [Mass/volume] in Serum or Plasma3.5mg/dL2.5-4.5 mg/dLNormalS
1997-02-10Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.4 mg/dLNormalS
1997-02-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma84U/L40-120 U/LNormalS
1997-02-10Parathyrin.intact [Mass/volume] in Serum or Plasma54pg/mL15-65 pg/mLNormalS
1997-02-10Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4 mIU/LNormalS
1997-02-10Hemoglobin [Mass/volume] in Blood13.3g/dL12-15.5 g/dLNormalS
1997-02-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
1997-02-1025-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mLTarget 30 ng/mL or higher before and during osteoporosis treatmentLowS
1997-02-10Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma560pg/mLPostmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates responseNormalS
1997-02-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
1997-02-10Total score [AUDIT-C]0{score}S
1997-05-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma38ng/mLTarget 30 ng/mL or higher before and during osteoporosis treatmentNormalS
1997-05-12Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
1997-05-12Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1 mg/dLNormalS
1997-05-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1992)/1.73 sq M81mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1997-05-12Calcium [Mass/time] in 24 hour Urine172mg/(24.h)100-300 mg/(24.h)NormalS
1997-08-11Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma190pg/mLPostmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates responseNormalS
1997-08-11Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1997-10-06Cholesterol [Mass/volume] in Serum or Plasma204mg/dL<=199 mg/dLHighS
1997-10-06Cholesterol in HDL [Mass/volume] in Serum or Plasma62mg/dL>=50 mg/dLNormalS
1997-10-06Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation118mg/dL<=129 mg/dLNormalS
1997-10-06Triglyceride [Mass/volume] in Serum or Plasma120mg/dL<=149 mg/dLNormalS
1997-10-06Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1997-10-06Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1997-02-10Body height164cmS
1997-02-10Body weight66kgS
1997-02-10Body mass index (BMI) [Ratio]24.5kg/m2S
1997-02-10Systolic blood pressure124mm[Hg]S
1997-02-10Diastolic blood pressure76mm[Hg]S
1997-02-10Heart rate72/minS
1997-02-10Respiratory rate14/minS
1997-02-10Body temperature36.6CelS
1997-02-10Oxygen saturation in Arterial blood by Pulse oximetry98%S
1997-03-10Body height164cmS
1997-03-10Body weight66.2kgS
1997-03-10Body mass index (BMI) [Ratio]24.6kg/m2S
1997-03-10Systolic blood pressure122mm[Hg]S
1997-03-10Diastolic blood pressure74mm[Hg]S
1997-03-10Heart rate70/minS
1997-03-10Respiratory rate14/minS
1997-03-10Body temperature36.7CelS
1997-03-10Oxygen saturation in Arterial blood by Pulse oximetry98%S
1997-05-12Body height164cmS
1997-05-12Body weight66.4kgS
1997-05-12Body mass index (BMI) [Ratio]24.7kg/m2S
1997-05-12Systolic blood pressure120mm[Hg]S
1997-05-12Diastolic blood pressure74mm[Hg]S
1997-05-12Heart rate72/minS
1997-05-12Respiratory rate14/minS
1997-05-12Body temperature36.6CelS
1997-05-12Oxygen saturation in Arterial blood by Pulse oximetry99%S
1997-08-11Body height164cmS
1997-08-11Body weight66kgS
1997-08-11Body mass index (BMI) [Ratio]24.5kg/m2S
1997-08-11Systolic blood pressure122mm[Hg]S
1997-08-11Diastolic blood pressure76mm[Hg]S
1997-08-11Heart rate68/minS
1997-08-11Respiratory rate14/minS
1997-08-11Body temperature36.7CelS
1997-08-11Oxygen saturation in Arterial blood by Pulse oximetry98%S
1997-10-06Body height164cmS
1997-10-06Body weight65.8kgS
1997-10-06Body mass index (BMI) [Ratio]24.5kg/m2S
1997-10-06Systolic blood pressure122mm[Hg]S
1997-10-06Diastolic blood pressure74mm[Hg]S
1997-10-06Heart rate70/minS
1997-10-06Respiratory rate14/minS
1997-10-06Body temperature36.6CelS
1997-10-06Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1997-02-10New patient visit for bone health after a fall with a hand fracturefinishedS
1997-03-10Four-week bone health review with endocrinology consultationfinishedS
1997-05-12Three-month bone health review and first zoledronic acid infusionfinishedS
1997-08-11Six-month bone health review, three months after the first infusionfinishedS
1997-10-06Adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Endocrinology consultation to confirm the diagnostic category from the T-scores and FRAX, the risk category, the choice of drug, the secondary-causes work-up, and the plan for monitoring and treatment durationcompletedGL-CMID-2026, GL-BHOF-2022, GL-AACE-2020, GL-ENDO-2019S
Drug treatment, because FRAX is above the treatment thresholds, with the agent confirmed at the endocrinology visit: zoledronic acid 5 mg intravenously once a year, given only after 25-hydroxyvitamin D is 30 ng/mL or more, calcium is normal, eGFR is above 35, and a routine dental examination is done; acetaminophen for the expected aches and fever after the first dose; reassess after three yearly doses for a drug holidaycompletedGL-CMID-2026, GL-BHOF-2022, GL-AACE-2020, GL-ENDO-2019, GL-ENDO-2020S
Calcium about 1200 mg a day in total, from food first, and vitamin D3 1971 units a day to reach 30 ng/mL or more, then continue; caffeine kept to two cups of coffee a day; no tobacco or alcoholcompletedGL-CMID-2026, GL-BHOF-2022, GL-AACE-2020S
Falls prevention by CDC STEADI: supervised balance and strength exercise with a physical therapist for eight weeks, then a home program three times a week; weight-bearing exercise most days; home safety review (stair rails, night lights, no loose rugs); low-heeled shoes when traveling; yearly vision checkcompletedGL-CDC-STEADI, GL-USPSTF-FALLS-2024, GL-BHOF-2022S
Monitoring on the CMID osteoporosis schedule: secondary-causes tests at baseline (calcium, albumin, phosphate, magnesium, alkaline phosphatase, creatinine and eGFR, PTH, 25-hydroxyvitamin D, TSH, blood count, and 24-hour urine calcium); calcium and creatinine before each infusion; fasting CTX at baseline and three to six months after starting; 25-hydroxyvitamin D after repletion and then yearly; height and fall-risk screen yearly; FRAX recalculated when risk factors change; DXA of the spine and hip two years after starting, on the same scannercompletedGL-CMID-2026, GL-AACE-2020, GL-ENDO-2019, GL-USPSTF-OSTEO-2025S
Recovery-oriented care for alcohol use disorder in sustained remission: ask about alcohol, cravings, and stress at each visit in a non-judgmental way, support the recovery practices she uses, avoid sedating medicines, and review safety with the 988 Suicide & Crisis Lifeline at each visitcompletedGL-SUD-2021, GL-SUICIDE-2024, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Total calcium intake of about 1200 mg a day, mostly from food, by the four-week visit1997-03-10completedAbout 1200 mg a day from food by her own three-day food recordS
25-hydroxyvitamin D of 30 ng/mL or more before the first infusion1997-05-12completed24 ng/mL at intake and 38 ng/mL at three monthsS
First zoledronic acid dose by the three-month visit, with normal calcium and kidney function and a dental check done1997-05-12completedGiven at three months after normal calcium (9.5 mg/dL) and eGFR (81) and a routine dental examinationS
Complete the eight-week balance and strength program, with no falls through six months1997-08-11completed16 of 16 sessions; Timed Up and Go 9 seconds and tandem stance 20 seconds at six months; no fallsS
Serum CTX at least 30 percent lower three months after the first dose1997-08-11completed560 pg/mL at baseline and 190 pg/mL at three months after the dose (66 percent lower)S
Sustained remission from alcohol use disorder throughout the episode1997-08-11completedNo alcohol reported at any visit; AUDIT-C 0 at intakeS

Functional Status

Mental Status

Structured synthetic safety assessment on 1997-02-10: current ideation absent, intent absent, plan absent. Routine outpatient care. Crisis resources, including the 988 Suicide & Crisis Lifeline, given in writing and saved in her phone; safety reviewed at each visit [S]